LabVantage Recognized as Top Growth and Innovation Leader by Frost & Sullivan in First Annual Global Life Sciences LIMS Report and Radar
19.10.2023 14:30:00 EEST | Business Wire | Press release
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today celebrated receiving global recognition as a top growth and innovation leader by Frost & Sullivan in the firm's first-ever Frost RadarTM: Global Laboratory Information Management Systems (LIMS) for the Life Sciences Industry 2023 Report. LabVantage earned the No. 1 ranking for growth on the Radar by securing high scores for its consistent growth trajectory, high market share, ability to capitalize on new growth opportunities, and commitment to continued innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231019604433/en/
LabVantage Solutions earned the top, outermost spot on the Frost Radar™, an independent comparative analytical benchmarking system, for its combined growth potential and ability to drive innovation. (Graphic: Business Wire)
The Frost Radar, created by growth advisory and analytics firm Frost & Sullivan, is an independent comparative analytical benchmarking tool that maps organizations and their LIMS solutions to identify top leaders in growth and innovation. Its growth index measures five parameters, including market share, revenue growth, growth pipeline, vision and strategy alignment, and sales and marketing effectiveness. The Radar’s innovation index evaluates scalability, research and development, product portfolio, leverage of long-term opportunities and new business models, and customer alignment. Using these indices, Frost & Sullivan benchmarked 120 LIMS solution vendors for the life sciences industry and represented the top 12 on the Radar as best-in-class solutions based on their features, capabilities, data integrity, interoperability, and informatics and analytics applications.
"Frost Radar Growth and Innovation leaders like LabVantage stand out because of their continuous innovation, comprehensive LIMS functionalities for life sciences companies, and regional commercial capabilities. They are instrumental in advancing the industry into the future,” said Piyush Bansal, Global Program Leader, at Frost & Sullivan. “The laboratory ecosystem is complex and requires tailored solutions for specific needs. LabVantage offers customers a best-in-class LIMS solution, reflected in its consistent growth and strong portfolio pipeline. Given its proven ability to scale continually, it has the potential to set an industry benchmark."
The Frost & Sullivan report recognizes LabVantage’s comprehensive product portfolio, the company’s hybrid approach of leveraging internal R&D and external collaborations to access new technology, and significant investments in artificial intelligence (AI) and Natural Language Processing (NLP) to adeptly manage both scientific and unstructured data. The report marks LabVantage as a ‘Company to Action’ and a primary driver of competitive intensity in its growth environment, noting the company’s significant future growth potential, best practices in the industry, and ability to amplify its customer value proposition. The report also honors LabVantage’s partnership potential and reputation as a significant value provider to customers, investors, value chain partners and prospective talent.
“We pioneered the integration of LIMS, ELN, LES, and SDMS into a comprehensive platform for lab informatics, continuously improving it in collaboration with our customers to provide valuable business intelligence. We are delighted to have our approach validated by such a respected industry voice as Frost & Sullivan,” said Mikael Hagstroem, Chief Executive Officer at LabVantage Solutions. “The Frost Radar report reinforces the need in the life science industry for a platform that delivers an integrated approach to solving the challenges of managing critical scientific data end-to-end, from R&D to manufacturing to quality control.”
LabVantage has strengthened its technological capabilities in the past year by acquiring Biomax Informatics and unveiling AILANI, a tool that synergizes semantic modeling, ontologies, linguistics, and AI algorithms and revolutionizes query-based research in various databases. Demonstrating commitment to leveraging growth prospects in emerging Latin America and increasing its footprint throughout the region, the company recently made two professional service acquisitions in Brazil and Colombia.
To see the Frost & Sullivan summary report, click here. For more information on LabVantage and its LIMS solutions, visit www.labvantage.com or email info@labvantage.com.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, forensic, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231019604433/en/
Contact information
Media Contact:
Charya Wickremasinghe, Ph.D.
Brandwidth Solutions
cwickremasinghe@brandwidthsolutions.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom